Early Engagement with HTA Bodies
In-depth guide to successful early HTA engagement.
Jim Gallagher2021 年 5 月 10 日
Evidence generation in Europe- How valuable is the French National administrative health data (SNDS)
Evidence generation in Europe- How valuable is the French National administrative health data (SNDS)
Watch this presentation to learn • Overview of the SNDS and the key working practices…
Jim Gallagher2021 年 5 月 7 日
The Wizard of Oligos: There’s no place like having a successful drug development program!
Oligonucleotide therapies— nucleic acid polymers with the potential to treat or manage a wide range…
Jim Gallagher2021 年 4 月 30 日
The Promises and Pitfalls of Gene Therapy for Rare Diseases
The state of gene therapy faces much uncertainty as recent regulatory and clinical setbacks have…
Jim Gallagher2021 年 4 月 29 日
Certara (CERT) – Accelerating Medicines with Biosimulation
As seen on CNBC** Certara is the global leader in biosimulation, a powerful and proven…
Jim Gallagher2021 年 4 月 27 日
Part 3: Oligonucleotide therapeutic development: Clinical pharmacology considerations
In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…
Jim Gallagher2021 年 4 月 21 日
